AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Wednesday 4 November 2026
News from the 24 hours to Wednesday morning, 4 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly positive, with brokers reiterating Buy ratings, solid quarterly results with unchanged guidance, and a favourable Delhi High Court outcome in a pricing case. A vaccine death case in Italy and a small share price dip were minor negatives.
What drove it
- quarterly results
- analyst ratings
- Delhi court relief
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 29 Oct | +2.8 | 13 |
| Fri 30 Oct | +6.3 | 13 |
| Sat 31 Oct | +8.7 | 78 |
| Sun 1 Nov | +6.3 | 8 |
| Mon 2 Nov | +9.2 | 15 |
| Tue 3 Nov | +7.5 | 28 |
| Wed 4 Nov | +5.0 | 19 |
10 stories · 19 headlines · strongest first
Pharma and healthcare on 4 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca Q3 results and $1.5bn savings plan +7.04 headlines today · 84 in all, since 31 October · Coverage of Q3 results covers the $1.5bn savings target, steady outlook and share reaction. | ||
| +7.5 | Shares continuing to rise after latest quarterly figures. | |
| +5.8 | Cost-saving target announced, within a wider deals roundup. | |
| +5.0 | Quarterly growth leaves full-year guidance unchanged. | |
| +2.5 | Solid quarter offset by declining product sales and flat shares. | |
| Brokers raise AstraZeneca targets after results +6.24 headlines today · 12 in all, since 3 November · Bernstein, Goldman Sachs and DZ Bank kept Buy ratings, and ratings forecasts were published. | ||
| +6.7 | Broker maintains positive recommendation. | |
| +6.7 | Major bank repeats positive recommendation. | |
| +6.7 | Another broker repeats positive recommendation. | |
| +5.0 | Analyst ratings with price targets implying upside. | |
| AstraZeneca India names new managing director +1.73 headlines today · Naveen Krishna Yamarthi has been appointed managing director of AstraZeneca's India business and head of its Chennai centre. | ||
| +1.7 | Routine leadership appointment at Indian unit and Chennai technology centre. | |
| +1.7 | Routine Indian leadership appointment. | |
| +1.7 | Routine leadership appointment in India. | |
| AstraZeneca Pharma India gets relief in overcharging case +5.02 headlines today · 6 in all, since 3 November · Delhi High Court gave AstraZeneca relief in a Rs 151 crore inhaler overcharging case. | ||
| +8.3 | Won court relief in pricing overcharge dispute in India. | |
| +8.3 | Favourable court outcome in inhaler pricing case. | |
| Etcamah pricing in oral SERD market +4.21 headline today · 2 in all, since 3 November · A piece argues that approval of Etcamah speeds up growth of the SERD market. | ||
| +7.5 | Regulatory approval of a cancer drug expected to support market growth. | |
| Judge urges Italian health authority to negotiate over vaccine death −6.71 headline today · A judge in Italy has pressed the Asl4 health authority to hold talks with the relatives of someone who died following an AstraZeneca vaccination. | ||
| −6.7 | Vaccine death case with legal pressure to negotiate with family. | |
| AstraZeneca AI to spot drug harm +5.01 headline today · An article looks at AstraZeneca using AI to detect first indications that a medicine is causing harm. | ||
| +5.0 | Exploring AI use for detecting drug safety issues early. | |
| AstraZeneca planning with OMP +4.21 headline today · An article describes AstraZeneca's development of constraint-based planning using OMP. | ||
| +4.2 | Case study of supply chain planning capability improvements. | |
| AstraZeneca slipped 1.0 percent among Nordic shares in North America −2.51 headline today · AstraZeneca fell 1.0% among Nordic stocks quoted in North America. | ||
| −2.5 | Minor one-percent share price dip in a regional roundup. | |
| Pfizer and AstraZeneca dividend comparison +0.81 headline today · A piece compares the dividends of Pfizer and AstraZeneca. | ||
| +0.8 | Dividend comparison with a rival, broadly neutral. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.